stockrow
Friday 6 November 2026
Export SUPN’s income statement to Excel — free account
Indivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
28.21
0.06
+0.21%
Follow SUPN
Alert me
| Older periods | Dec '25 | Mar '26 | Jun '26 | Sep '26 | |
|---|---|---|---|---|---|
Piotroski F-Score |
+8 more TTM periods Free account |
4 | 5 | 4 | 7 |
| (96.33%) | (117.21%) | (153.12%) | (337.83%) | ||
| 16.69% | 19.60% | 26.52% | 32.82% | ||
ROIC |
629.81% | 124.25% | 460.53% | 283.03% | |
Return on Tangible Assets |
(177.97%) | 560.00% | 1,873.68% | (138.34%) | |
Average Days of Receivables |
75.12 | 80.64 | 78.70 | 76.03 | |
Free Cash Flow per Share |
(0.76) | (1.55) | (0.93) | 0.26 | |
Free Cash Flow |
(95.00) | (192.00) | (111.00) | 31.00 | |
Capital Expenditures |
(68.00) | (81.00) | (71.00) | (65.00) | |
| Other line items | |||||
Cash ROIC |
(22.84%) | (37.14%) | (22.16%) | 4.23% | |
Accounts Receivable Turnover |
4.57 | 4.63 | 5.02 | 4.92 | |
Accounts Payable Turnover |
1.06 | 1.34 | 1.19 | 1.05 | |
Inventory Turnover |
1.54 | 1.54 | 1.61 | 1.37 | |
Average Days of Payables |
370.94 | 268.47 | 313.29 | 317.62 | |
Days of Inventory on Hand |
227.01 | 229.26 | 228.13 | 261.47 | |
Tax Rate |
(0.12) | (0.15) | (0.10) | (0.16) | |
Research and Development Expense of Revenue |
7.83% | 7.05% | 6.16% | 3.93% | |
Selling, General and Administrative Expense of Revenue |
51.17% | 48.45% | 44.25% | 40.35% | |
Share Based Compensation of Revenue |
2.10% | 2.25% | 2.40% | 2.40% | |
Interest Coverage |
5.82 | 8.30 | 15.56 | 32.76 | |
Operating CF/Net income |
(0.13) | (0.44) | (0.11) | 0.21 | |
Depreciation/Fixed assets |
0.14 | 0.12 | 0.10 | 0.08 | |
Capex/Depreciation |
(3.40) | (4.26) | (4.18) | (4.64) | |
Revenue per Share |
9.91 | 10.40 | 11.18 | 11.64 | |
Operating CF per Share |
(0.22) | (0.90) | (0.34) | 0.81 | |
Capex per Share |
(0.54) | (0.65) | (0.60) | (0.55) | |
Capex to Sales |
0.05 | 0.06 | 0.05 | 0.05 |
Columns are period end dates · fundamentals updated 2 Nov 2026